New drug development for Chinese medicine, integrating CMC, pharmacology, toxicology, and regulatory registration to translate traditional formulations into modern therapeutics. Current interests include standardisation and chemical fingerprinting of multi-component products, translational PK/TK and GLP safety, elucidating mechanisms of action, SEND-enabled nonclinical packages, and efficient, evidence-based pathways to Phase I/II studies.